Roche’s response to the COVID-19 pandemic

Our commitment to help put a stop to the COVID-19 pandemic


Roche is deeply committed to supporting the global response to put an end to the COVID-19 pandemic. Around the world, we are working with urgency, passion and purpose each and every day to deliver high quality tests that are essential for healthcare systems and patients alike.


Timely availability and fast access to reliable, high quality tests are essential for healthcare systems.


Thomas Schinecker
Chief Executive Officer of Roche Diagnostics

Detecting SARS-CoV-2 in currently infected patients with high sensitivity

Laboratory tests


Molecular test (PCR)


The cobas® SARS-CoV-2 Test is a real-time RT-PCR test intended for the qualitative detection of SARS-CoV-2 in nasopharyngeal and oropharyngeal swab samples from patients.

cobas® SARS-CoV-2 Test


This test can run on Roche’s fully automated cobas® 6800 and cobas® 8800 Systems under Emergency Use Authorisation. Both tests are also available for countries accepting the CE-mark.

cobas® 6800 System

cobas® 8800 System

Point of Care tests


Molecular test (PCR)


The cobas® SARS-CoV-2 & Influenza A/B Assay is an automated multiplex real-time RT-PCR assay intended for the simultaneous rapid in vitro qualitative detection and differentiation of SARS-CoV-2., influenza A, and influenza B in nasopharyngeal and nasal swabs from patients suspected of respiratory viral infection.


The test is run on Roche's molecular point-of-care PCR testing solution, the cobas® Liat® System, under Emergency Use Authorisation. It is also available for countries accepting the CE-mark.

cobas® Liat® System

Rapid antigen test


The SARS-CoV-2 Rapid Antigen Test is a reliable, rapid chromatopgraphic immunoassay for the qualitative detection of specific antigens of SARS-CoV-2 present in the human nasopharynx.

SARS-CoV-2 Rapid Antigen Test

How the SARS-CoV-2 Rapid Antigen Test works

Detecting a patient’s immune response to SARS CoV-2 with high specificity

Laboratory tests


Antibody test


Elecsys® Anti-SARS-CoV-2 is an immunoassay for the in vitro qualitative detection of antibodies (including IgG) to SARS-CoV-2 in human serum and plasma. The test is intended as an aid in the determination of the immune reaction to SARS-CoV-2.

Elecsys® Anti-SARS-CoV-2


Elecsys® Anti-SARS-CoV-2 S is an immunoassay for the in vitro quantitative determination of antibodies (including IgG) to the SARS-CoV-2 spike (S) protein receptor-binding domain (RBD) in human serum and plasma.

Elecsys® Anti-SARS-CoV-2 S


The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analysers.

cobas e 801 analytical unit

Point of Care tests


Rapid antibody test


The SARS-CoV-2 Rapid Antibody Test is a reliable, rapid chromatographic immunoassay intended for qualitative detection of antibodies (IgM and IgG) to SARS-CoV-2 in human serum, plasma or whole blood.

The test is intended for the use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating prior infection.

SARS-CoV-2 Rapid Antibody Test

How the SARS-CoV-2 Rapid Antibody Test works

When to use which
SARS‑CoV‑2 diagnostic test1


Reliable diagnostic tests targeting patients that are currently infected by the virus, as well as those that have an immune response against the virus, are valuable. However, it is important to understand which tests are most suitable to use depending on their intended purpose.

icon of a person

Is my sickness COVID‑19?

Tests that detect the virus


See more

icon of a person

How is my body's immune system reacting to the virus?

Tests that detect immune response and potential immunity*


See more

*Whether immunity is gained by individuals who have been infected with SARS-CoV-2 is yet to be confirmed due to the novelty of the virus. Data presented here are based on current scientific understanding of the disease (April 2020)



COVID-19: coronavirus disease 2019

RT-PCR: reverse transcription polymerase chain reaction

  1. European Commision (2020). Guidelines on COVID-19 in vitro diagnostic tests and their performance (published 15 April 2020). Available from [Accessed April 2020]